FDA official offers perspective on treatments vs. cures

FORT LAUDERDALE, Fla. — Difficult questions face companies looking to develop new treatments for ophthalmic conditions and for those who hope to have their agents approved by the FDA, a speaker said here.
Sustained-release therapies, therapies that block additional factors and gene therapies hold great promise as treatments, but they raise difficult questions about how they should work, how they should be introduced to a patient and how they address the signs and symptoms of the condition they are treating, Wiley Chambers, MD, an ophthalmologist with the FDA Center for (Read more...)

Full Story →